Hls Therapeutics Stock Today
| HLTRF Stock | USD 2.60 0.00 0.00% |
Performance5 of 100
| Odds Of DistressOver 55
|
HLS Therapeutics is trading at 2.60 as of the 4th of December 2024. This is a No Change since the beginning of the trading day. The stock's lowest day price was 2.6. HLS Therapeutics has over 55 % chance of experiencing financial distress in the next 2 years of operation and did not have a very good performance during the last 90 trading days. Equity ratings for HLS Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 4th of November 2024 and ending today, the 4th of December 2024. Click here to learn more.
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. HLS Therapeutics Inc. was founded in 2018 and is headquartered in Etobicoke, Canada. The company has 32.38 M outstanding shares. More on HLS Therapeutics
Moving against HLS Pink Sheet
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
HLS Pink Sheet Highlights
| Business Concentration | Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) |
HLS Therapeutics [HLTRF] is a Pink Sheet which is traded through a dealer network over-the-counter (OTC). The company currently falls under 'Small-Cap' category with a current market capitalization of 231.54 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate HLS Therapeutics's market, we take the total number of its shares issued and multiply it by HLS Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. HLS Therapeutics classifies itself under Healthcare sector and is part of Drug Manufacturers—Specialty & Generic industry. The entity has 32.38 M outstanding shares.
HLS Therapeutics has accumulated about 21.16 M in cash with 16.43 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.65.
Check HLS Therapeutics Probability Of Bankruptcy
Ownership AllocationHLS Therapeutics has a total of 32.38 Million outstanding shares. Over half of HLS Therapeutics' outstanding shares are owned by outside corporations. These outside corporations are typically referred to as corporate investors that purchase positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check HLS Ownership Details
HLS Therapeutics Risk Profiles
| Mean Deviation | 1.48 | |||
| Semi Deviation | 2.58 | |||
| Standard Deviation | 3.32 | |||
| Variance | 11.04 |
HLS Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in HLS Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Stock Tickers Now
Stock TickersUse high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites |
| All Next | Launch Module |
HLS Therapeutics Corporate Management
| BA LLB | CoFounder Chairman | Profile | |
| Sanjiv Sharma | Chief Officer | Profile | |
| JD BA | HR Legal | Profile | |
| David Spence | Co Controller | Profile | |
| Gilbert Godin | CEO CoFounder | Profile | |
| Tim MBA | Chief Officer | Profile |
Other Information on Investing in HLS Pink Sheet
HLS Therapeutics financial ratios help investors to determine whether HLS Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in HLS with respect to the benefits of owning HLS Therapeutics security.